China SXT Pharmaceuticals, Inc. (SXTC) Stock Analysis

Company Overview

The market values China SXT Pharmaceuticals, Inc. (SXTC) at $1.19M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 56 employees.

The most recent close on file for SXTC is $2.23, dated September 4, 2026. That is +$0.03 (+1.36%) against the previous close. The 52-week range on file runs from $2.06 to $83,760.00. The latest close sits 8.25% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.14M. That is −34.63% against the prior fiscal year, when revenue was $1.74M. The same year closed with a net loss of $6.21M. Profit margin runs at 0%. That is 3.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −730.4.

Across the 4 fiscal years on file, revenue moves from $1.97M in 2022 to $1.14M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.05. On price-to-sales that is 54.43% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is −98.92%. Across 5 years the annualized return works out at −77.95%. The reported beta is 1.84. Annualized volatility over the trailing 7 years is 3,018.59%.

Growth & Income

The record shows no dividend for SXTC.

The strongest complete calendar year on file is 2025 at +214.96%; the weakest is 2024 at −87.20%. Of the 7 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −99.07% year to date.